Drug Trial Radar · NCT02032823
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,837
Actual
Start
Apr 22, 2014
Primary completion
Mar 27, 2020
Study completion May 28, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Frontier Science & Technology Research Foundation, Inc.; NRG Oncology; Myriad Genetic Laboratories, Inc.; The Breast Adjuvant Study Team; Merck Sharp & Dohme LLC
- First posted
- Jan 10, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
Conditions
- Breast Cancer
Interventions
OlaparibDrug
Patients will be administred olaparib orally twice daily (b.i.d.) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water
PlaceboDrug
Patients will be administred matching placebo. Two (2) tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Disease Free Survival (IDFS)Time frame: From date of randomisation to data cut off: 27 March 2020 (approximately 5 years 11 months)
Locations
698 sites in 24 countries. Site status is shown where the registry gives one.
Research Site
Anchorage, Alabama
Research Site
Anchorage, Alaska
Research Site
Gilbert, Arizona
Research Site
Fort Smith, Arkansas
Research Site
Baldwin Park, California
Research Site
Berkeley, California
Research Site
Duarte, California
Research Site
Fontana, California
Research Site
Fresno, California
Research Site
Greenbrae, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Martinez, California
Research Site
Newport Beach, California
Research Site
Oakland, California
Research Site
Palo Alto, California
Research Site
Paradise, California
Research Site
Roseville, California
Research Site
Roseville, California
Research Site
Sacramento, California
Research Site
San Francisco, California
Research Site
San Jose, California
Research Site
San Leandro, California
Research Site
San Marcos, California
Research Site
Santa Cruz, California
Research Site
Santa Rosa, California
Research Site
South San Francisco, California
Research Site
Stockton, California
Research Site
Sunnyvale, California
Research Site
Sunnyvale, California
Research Site
Vacaville, California
Research Site
Vallejo, California
Research Site
Woodland Hills, California
Research Site
Aurora, Colorado
Research Site
Colorado Springs, Colorado
Research Site
Denver, Colorado
Research Site
Edwards, Colorado
Research Site
Fort Collins, Colorado
Showing 40 of 698 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.